Anna Rivkin Global Lead, Fibrotic Diseases [email protected]
Ildiko Antal Associate, Specialty [email protected]
Mohamed Ragab Head, Immuno-Oncology/Oncology [email protected]
Timothy Fisher Global Lead, Immuno-Oncology/Oncology [email protected]
Saryah Azmat Associate, Immuno-Oncology/Oncology [email protected]
TECHNOLOGY TRANSACTIONS
Donnie McGrath Vice President, Search and Evaluation
Steve Yoder Head, Specialty [email protected]
Martin Crook Global Lead, Cardiovascular [email protected]
Mireia Gomez-Angelats Global Lead, Genetically Defined Diseases [email protected]
Stephen O’Keefe Global Lead, Immunoscience stephen.o’[email protected]
SEARCH AND EVALUATION
Graham Brazier Vice President, Transactions
Matt Bunn Genomics, Bioinformatics and Clinical Imaging [email protected]
Michael Cucolo Drug Delivery and Formulation Sciences [email protected]
Andrea Lauber Clinical Biomarkers and Pharmacodiagnostics [email protected]
Karen Martell Biologics Discovery Platforms [email protected]
Rob Penhallow Chemistry and ADME/Toxicology [email protected]
Ping Cao Lead Discovery and Optimization and Protein Sciences and Structure [email protected]
For more information please visit: www.bms.com/partnering
5asd
- Paul Biondi, Senior Vice President Head, Business Development ”“Business development is a key component
of Bristol-Myers Squibb’s strategy and has strengthened and diversified our portfolio for long-term growth.
Working together for patients.
PARTNERING EXTERNAL INNOVATION
AND
5asd
BUSINESS DEVELOPMENT CONTACTS
OUR STRATEGIC FOCUS - 2016
Immuno-Oncology
• Focus on approaches that are direct acting on the immune system
- Novel immune checkpoint inhibitors and co-stimulatory agents
• Tumor intrinsic targets with demonstrated impact on anti-tumor immunity
• Tumor microenvironment
Oncology • Agents displaying synergy with immune
checkpoint inhibitors
• Established non-immunosuppressive mechanisms of action
• New approaches to validated cancer pathways
• Emerging areas of cancer biology
• Antibody drug conjugates (ADC) – novel targets and late preclinical/clinical-stage programs in areas of unmet medical need
• Out of Scope: Supportive care – BMS focuses on therapeutics
Immunoscience
• Assets with transformative potential in IBD, inflammatory arthritis, SLE/lupus nephritis and other autoimmune diseases with high unmet needs
• Out of Scope: allergy and asthma
Cardiovascular • Heart failure: acute, post-acute, HFrEF, HFpEF,
cardiomyopathy
• Highly validated targets addressing CV risk with clear specialty medicine development paths
• Out of Scope: LDL lowering, HDL raising, anticoagulant, hypertension
Fibrosis • Mechanisms that specifically block myofibroblast
activation/differentiation and profibrotic macrophage activation
• Targeted inhibition of TGF-beta and other developmental pathways
• Approaches and mechanisms that target matrix re-modeling, epithelial cell protection and repair
• New anti-fibrotic mechanisms with data supporting target validation and some safety understanding
• Non-invasive diagnostics and biomarkers
• Priority fibrotic diseases include: NASH, idiopathic pulmonary fibrosis, systemic sclerosis, IgA nephropathy
• Out of Scope: Eye fibrosis, wound healing, keloids, uterine (endometriosis)
Genetically Defined Diseases (GDD)
• Focus on monogenic diseases
• Clinical-stage opportunities in rare/orphan diseases targeting at or near mutant protein
• Special interest in clinical and preclinical opportunities targeting Duchenne Muscular Dystrophy, synuclein, Nav1.7, and familial cardiomyopathy (fCM – hypertrophic or dilated)
BRISTOL-MYERS SQUIBB DEVELOPMENT PORTFOLIO BY DISEASE AREA
Fibrotic Diseases Genetically Defined DiseasesImmuno-Oncology ImmunoscienceOncology Cardiovascular
YERVOY
Virology
OPDIVO
EMPLICITI
Prostvac
Urelumab (Anti-CD137)
Lirilumab (Anti-KIR)
Anti-LAG3
SPRYCEL ORENCIA
NULOJIX
Lulizumab (Anti-CD28)
Anti-CD40
Anti-CD40L
BTK Inhibitor
TYK2 Inhibitor
REYATAZ/EVOTAZ
DAKLINZA
SUNVEPRA 3
Beclabuvir (NS5B Non Nuc)
HIV Attachment Inhibitor*
HIV Maturation Inhibitor*
Anti-PD-L1
ELIQUIS
IKur Inhibitor
Factor XIa Inhibitor
PEG-FGF21 (1)
Galectin-3 Inhibitor
Anti-eTau
Anti-Myostatin
▶▶
▶▶
▶▶
▶
▶▶
▶▶
▶
▶
▶▶
Data as of December, 2015
BET Inhibitor▶
LPA1 Antagonist
PAR4 Antagonist
Ulocuplumab (Anti-CXCR4)
Anti-Fucosyl GM1
Anti-HER2
▶▶
▶
Mesothelin-ADC▶TECHNOLOGY INTERESTS
“ ”Developing cutting-edge science in our own labs and in collaboration with partners is critical to our ability to deliver transformational medicines to patients.- Giovanni Caforio, M.D. Chief Executive Officer
1 Approved in at least one major market (US, EU, JP)
2 In Phase III development or currently under regulatory review
3 Not approved in the U.S.
Marketed 1
Phase III 2
Phase II
Phase I
▶ Biologics
Small Molecules
Partnered or in Collaboration
DRUG PLATFORMS AND NOVEL TECHNOLOGIES
• Access to new chemical matter, including macrocycle and fragment libraries
• Novel antibody drug conjugate (ADC) technology
• Subcutaneous controlled release
• Oral delivery of millamolecules and macrocyclic peptides
• ADME/Toxicology: Modeling and prediction technology
• High throughput, label free screening and protein expression platform
• Emerging structure determination platform
• Non-invasive diagnostics and translational biomarkers
• Improved methods for single cell capture, and genomic characterization
• Scalable bioinformatics analysis capabilities using principles for reproducible research
Anti-GITR
Anti-CSF 1R
▶▶
Nitroxyl Donor
Pentraxin-2
PEG-FGF21(2)▶▶
Gene TherapyRNA Oligonucleotides
Small Molecules Biologics
Antibody Drug Conjugates Millamolecules
Drug Delivery Technology
* included in pending sale of HIV R&D assets to ViiV Healthcare